Allarity Therapeutics (NASDAQ:ALLR) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Allarity Therapeutics (NASDAQ:ALLR) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Separately, Ascendiant Capital Markets started coverage on shares of Allarity Therapeutics in a research report on Monday, July 28th. They issued a “buy” rating and a $9.00 price target on the stock. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $9.00.

Allarity Therapeutics Trading Up 15.6%

Allarity Therapeutics stock opened at $1.78 on Friday. The stock has a fifty day moving average price of $1.26 and a two-hundred day moving average price of $1.07. Allarity Therapeutics has a 52-week low of $0.61 and a 52-week high of $2.40.

Allarity Therapeutics (NASDAQ:ALLR) last issued its earnings results on Friday, August 15th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06. On average, equities research analysts predict that Allarity Therapeutics will post -78.08 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ALLR. XTX Topco Ltd acquired a new stake in shares of Allarity Therapeutics in the 2nd quarter valued at $51,000. Geode Capital Management LLC boosted its holdings in Allarity Therapeutics by 49.3% in the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after acquiring an additional 16,729 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in Allarity Therapeutics in the second quarter valued at about $27,000. 11.53% of the stock is currently owned by institutional investors.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.